Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy
- PMID: 38016356
- PMCID: PMC10698329
- DOI: 10.1016/j.tranon.2023.101838
Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy
Abstract
As a clinically approved treatment strategy, chemotherapy-mediated tumor suppression has been compromised, and in spite of introducing various kinds of anticancer drugs, cancer eradication with chemotherapy is still impossible. Chemotherapy drugs have been beneficial in improving the prognosis of cancer patients, but after resistance emerged, their potential disappeared. Oxaliplatin (OXA) efficacy in tumor suppression has been compromised by resistance. Due to the dysregulation of pathways and mechanisms in OXA resistance, it is suggested to develop novel strategies for overcoming drug resistance. The targeted delivery of OXA by nanostructures is described here. The targeted delivery of OXA in cancer can be mediated by polymeric, metal, lipid and carbon nanostructures. The advantageous of these nanocarriers is that they enhance the accumulation of OXA in tumor and promote its cytotoxicity. Moreover, (nano)platforms mediate the co-delivery of OXA with drugs and genes in synergistic cancer therapy, overcoming OXA resistance and improving insights in cancer patient treatment in the future. Moreover, smart nanostructures, including pH-, redox-, light-, and thermo-sensitive nanostructures, have been designed for OXA delivery and cancer therapy. The application of nanoparticle-mediated phototherapy can increase OXA's potential in cancer suppression. All of these subjects and their clinical implications are discussed in the current review.
Keywords: Chemoresistance; Gene and drug delivery; Oxaliplatin; Synergistic cancer therapy; Targeted delivery.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures





Similar articles
-
Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer.Biomaterials. 2022 Nov;290:121827. doi: 10.1016/j.biomaterials.2022.121827. Epub 2022 Sep 27. Biomaterials. 2022. PMID: 36228517
-
Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy.Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. Epub 2023 Aug 9. Biomed Pharmacother. 2023. PMID: 37567073 Review.
-
(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy.Med Res Rev. 2023 Nov;43(6):2115-2176. doi: 10.1002/med.21971. Epub 2023 May 11. Med Res Rev. 2023. PMID: 37165896 Review.
-
Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.Acta Biomater. 2022 Nov;153:465-480. doi: 10.1016/j.actbio.2022.09.027. Epub 2022 Sep 14. Acta Biomater. 2022. PMID: 36115656
-
Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application.Int J Biol Macromol. 2023 Jul 1;242(Pt 3):124935. doi: 10.1016/j.ijbiomac.2023.124935. Epub 2023 May 23. Int J Biol Macromol. 2023. PMID: 37230442 Review.
Cited by
-
Molecular Hydrogen Protects against Various Tissue Injuries from Side Effects of Anticancer Drugs by Reducing Oxidative Stress and Inflammation.Biomedicines. 2024 Jul 17;12(7):1591. doi: 10.3390/biomedicines12071591. Biomedicines. 2024. PMID: 39062164 Free PMC article. Review.
-
T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies.ACS Appl Bio Mater. 2024 May 20;7(5):2637-2659. doi: 10.1021/acsabm.4c00074. Epub 2024 Apr 30. ACS Appl Bio Mater. 2024. PMID: 38687958 Free PMC article. Review.
References
-
- Santoni M., Rizzo A., Kucharz J., Mollica V., Rosellini M., Marchetti A., Tassinari E., Monteiro F.S.M., Soares A., Molina-Cerrillo J., et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol. Immunother. 2023;72:1365–1379. doi: 10.1007/s00262-022-03349-4. - DOI - PMC - PubMed
-
- Santoni M., Rizzo A., Mollica V., Matrana M.R., Rosellini M., Faloppi L., Marchetti A., Battelli N., Massari F. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit. Rev. Oncol. Hematol. 2022;170 doi: 10.1016/j.critrevonc.2022.103596. - DOI - PubMed
-
- Ricci, A.D.; Rizzo, A.; Brandi, G. DNA damage response alterations in gastric cancer: knocking down a new wall. 2021, 17, 865–868. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials